Novel agents under investigation
| Target . | Name of agent . | Status . |
|---|---|---|
| Drug class: small-molecule inhibitor | ||
| BTK | Ibrutinib (PCI-32765) | Approved |
| Acalabrutinib (ACP-196) | Investigational | |
| BGB-311 | Investigational | |
| ONO-4059 (GS-4059) | Investigational | |
| PI3K | Idelalisib (GS-1101, CAL-101) | Approved |
| Duvelisib (IPI-145) | Investigational | |
| TGR-1202 | Investigational | |
| Buparlisib (BKM-120) | Investigational | |
| GS-9820 | Investigational | |
| AMG-319 | Investigational | |
| SAR245408 | Investigational | |
| Syk | Fostamatinib (R788, R406) | Investigational |
| Entospletinib (GS-9973) | Investigational | |
| Src | Dasatinib | Approved (not in CLL) |
| Bcl-2 | Venetoclax (ABT-199) | Approved |
| CDK | Alvocidib (flavopiridol) | Investigational |
| Dinaciclib | Investigational | |
| Palbociclib (PD-0332991) | Approved (not in CLL) | |
| Drug class: immunotherapy | ||
| CD20 | Rituximab | Approved |
| Ofatumumab | Approved | |
| Obinutuzumab | Approved | |
| CD19 | CAR T cells | Investigational |
| CD19/CD3 | Blinatumomab | Approved (not in CLL) |
| BiTE | ||
| CD37 | TRU-016 | Investigational |
| CD37 (ADC) | IMGN529 | Investigational |
| PD-1 | Pembrolizumab (MK-3475) | Approved (not in CLL) |
| Target . | Name of agent . | Status . |
|---|---|---|
| Drug class: small-molecule inhibitor | ||
| BTK | Ibrutinib (PCI-32765) | Approved |
| Acalabrutinib (ACP-196) | Investigational | |
| BGB-311 | Investigational | |
| ONO-4059 (GS-4059) | Investigational | |
| PI3K | Idelalisib (GS-1101, CAL-101) | Approved |
| Duvelisib (IPI-145) | Investigational | |
| TGR-1202 | Investigational | |
| Buparlisib (BKM-120) | Investigational | |
| GS-9820 | Investigational | |
| AMG-319 | Investigational | |
| SAR245408 | Investigational | |
| Syk | Fostamatinib (R788, R406) | Investigational |
| Entospletinib (GS-9973) | Investigational | |
| Src | Dasatinib | Approved (not in CLL) |
| Bcl-2 | Venetoclax (ABT-199) | Approved |
| CDK | Alvocidib (flavopiridol) | Investigational |
| Dinaciclib | Investigational | |
| Palbociclib (PD-0332991) | Approved (not in CLL) | |
| Drug class: immunotherapy | ||
| CD20 | Rituximab | Approved |
| Ofatumumab | Approved | |
| Obinutuzumab | Approved | |
| CD19 | CAR T cells | Investigational |
| CD19/CD3 | Blinatumomab | Approved (not in CLL) |
| BiTE | ||
| CD37 | TRU-016 | Investigational |
| CD37 (ADC) | IMGN529 | Investigational |
| PD-1 | Pembrolizumab (MK-3475) | Approved (not in CLL) |
BiTE, bispecific T-cell engager.